Published in Osteoporos Int on June 19, 2007
Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int (2008) 0.95
Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. Osteoporos Int (2010) 0.86
Perception, knowledge, and use by general practitioners of Belgium of a new WHO tool (FRAX) to assess the 10-year probability of fracture. Rheumatol Int (2012) 0.83
Bone quality: educational tools for patients, physicians, and educators. Clin Orthop Relat Res (2011) 0.77
Physicians' perspectives on the treatment of osteoporosis patients with bisphosphonates. Clin Interv Aging (2016) 0.75
Self-reported calcium use in a cohort of postmenopausal women receiving osteoporosis therapy: results from POSSIBLE US™. Osteoporos Int (2015) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res (2007) 14.84
Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 12.60
High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc (2006) 8.78
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
Predictive value of BMD for hip and other fractures. J Bone Miner Res (2005) 6.46
Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab (2005) 5.64
Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med (2002) 2.98
The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med (2006) 2.78
Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum (2006) 2.73
American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract (2004) 2.69
National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med (2004) 2.35
Population trends in BMD testing, treatment, and hip and wrist fracture rates: are the hip fracture projections wrong? J Bone Miner Res (2004) 2.15
Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc (2002) 1.99
National Consensus Conference on Improving the Continuum of Care for Patients with Hip Fracture. J Bone Joint Surg Am (2002) 1.87
Information needs in the management of osteoporosis in family practice: an illustration of the failure of the current guideline implementation process. Osteoporos Int (2003) 1.86
Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res (2002) 1.58
Recommendations for estrogen and progestogen use in peri-and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause (2004) 1.57
Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med (2006) 1.55
Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med (2003) 1.50
Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc (2005) 1.32
Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int (2000) 1.28
Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res (2003) 1.20
Management of osteoporosis: a survey of Israeli physicians' knowledge and attitudes. Isr Med Assoc J (2000) 1.18
Patterns of use of the bone mineral density test in Ontario, 1992-1998. CMAJ (2000) 1.14
Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact (2004) 1.10
Prescriptions for estrogen replacement therapy in Ontario before and after publication of the Women's Health Initiative Study. JAMA (2003) 1.06
Knowledge and opinions of orthopaedic surgeons concerning medical evaluation and treatment of patients with osteoporotic fracture. J Bone Joint Surg Am (2006) 0.97
Management of osteoporosis in general practice: a cross-sectional survey of primary care practitioners in Spain. Osteoporos Int (2004) 0.95
Attitudes and beliefs of family physicians and gynecologists in relation to the prevention and treatment of osteoporosis. J Bone Miner Res (1997) 0.93
Multinational survey of osteoporotic fracture management. Osteoporos Int (2004) 0.91
Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause (2002) 0.90
Design of NORA, the National Osteoporosis Risk Assessment Program: a longitudinal US registry of postmenopausal women. Osteoporos Int (1998) 0.89
Factors related to the use of bone densitometry: survey responses of 494 primary care physicians in New England. Osteoporos Int (2003) 0.83
How useful are measures of BMD and bone turnover? Curr Med Res Opin (2005) 0.80
Trends and determinants of antiresorptive drug use for osteoporosis among elderly women. Pharmacoepidemiol Drug Saf (2005) 0.79
Osteoporosis prevention: pediatricians' knowledge, attitudes, and counseling practices. Prev Med (2002) 0.79
Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep (2005) 0.77
Awareness, attitudes and opinions on osteoporosis of primary care physicians working in the metropolitan area of Rome: a brief report. Aging (Milano) (2000) 0.75
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care (1995) 10.36
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Patients' ratings of outpatient visits in different practice settings. Results from the Medical Outcomes Study. JAMA (1993) 6.09
Central obesity and increased risk of dementia more than three decades later. Neurology (2008) 6.03
The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia. Am Rev Respir Dis (1971) 4.88
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med (1990) 4.10
Differences between respondents and non-respondents in a population-based cardiovascular disease study. Am J Epidemiol (1978) 3.90
Patient preferences for medical decision making: who really wants to participate? Med Care (2000) 3.89
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
A classification of marginal tissue recession. Int J Periodontics Restorative Dent (1985) 3.62
Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation (1987) 3.49
Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology (2004) 3.47
Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. Medicine (Baltimore) (1971) 3.40
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med (1993) 3.23
Skeletal disease in primary hyperparathyroidism. J Bone Miner Res (1989) 3.00
Frequency or probability? A qualitative study of risk communication formats used in health care. Med Decis Making (2001) 2.90
The prevalence of peripheral arterial disease in a defined population. Circulation (1985) 2.88
Evaluation of the MOS SF-36 physical functioning scale (PF-10): I. Unidimensionality and reproducibility of the Rasch item scale. J Clin Epidemiol (1994) 2.79
Latent and chronic infections imported from Southeast Asia. JAMA (1978) 2.78
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet (1985) 2.62
The epidemiology of head injury: a prospective study of an entire community-San Diego County, California, 1978. Am J Epidemiol (1981) 2.58
Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA (1983) 2.57
Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol (1994) 2.50
Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med (1998) 2.41
Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation (1999) 2.31
Exercise patterns in a population of older adults. Am J Prev Med (1989) 2.28
The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int (2006) 2.24
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med (1986) 2.18
Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation (1997) 2.17
Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study. Am J Epidemiol (1982) 2.15
Cognitive and functional status of the oldest old. J Am Geriatr Soc (1996) 2.14
Effects of passive smoking on ischemic heart disease mortality of nonsmokers. A prospective study. Am J Epidemiol (1985) 2.12
Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation (2001) 2.12
Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res (1997) 2.11
Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol (1997) 2.06
A prospective population-based study of alcohol use and non-insulin-dependent diabetes mellitus. Am J Epidemiol (1990) 2.05
Dietary calcium and risk of hip fracture: 14-year prospective population study. Lancet (1988) 2.05
Eosinophilic prostatitis and prostatic specific antigen. Br J Urol (1992) 2.04
The effect of parity on the later development of non-insulin-dependent diabetes mellitus or impaired glucose tolerance. N Engl J Med (1989) 2.03
Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res (1997) 2.03
A prospective study of alcohol consumption and bone mineral density. BMJ (1993) 1.99
Depressive symptoms in overweight and obese older adults: a test of the "jolly fat" hypothesis. J Psychosom Res (1996) 1.97
Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med (1998) 1.96
Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev (1985) 1.95
Dietary potassium and stroke-associated mortality. A 12-year prospective population study. N Engl J Med (1987) 1.95
GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care (1996) 1.90
Physical exercise, sports, and lung function in smoking versus nonsmoking adolescents. Eur Respir J (2002) 1.89
Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab (2000) 1.88
Cigarette smoking and levels of adrenal androgens in postmenopausal women. N Engl J Med (1988) 1.88
Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med (2001) 1.87
Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol (1998) 1.86
Health problems in teenage daily smokers versus nonsmokers, Norway, 1995-1997: the Nord-Trøndelag Health Study. Am J Epidemiol (2000) 1.85
Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int (1993) 1.84
Relation between body size and bone mineral density in elderly men and women. Am J Epidemiol (1993) 1.81
Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med (1999) 1.81
Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract (2001) 1.81
The postwar hospitalization experience of U.S. veterans of the Persian Gulf War. N Engl J Med (1996) 1.77
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Impact of obesity on health-related quality of life in patients with chronic illness. J Gen Intern Med (2000) 1.76
The effect of response bias on the odds ratio. Am J Epidemiol (1981) 1.73
Family history of heart attack as an independent predictor of death due to cardiovascular disease. Circulation (1984) 1.73
Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol (1998) 1.70
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
Ischemic heart disease risk factors after age 50. J Chronic Dis (1984) 1.69
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol (1983) 1.66
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J Clin Endocrinol Metab (2015) 1.61
Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos Int (2007) 1.61
Diabetes and pancreatic carcinoma. Diabete Metab (1994) 1.59
Estrogen replacement therapy and the risk of venous thrombosis. Am J Med (1992) 1.58
A prospective study of Type 2 diabetes and depressive symptoms in the elderly: the Rancho Bernardo Study. Diabet Med (2004) 1.58
Management of prolonged pregnancy: induction of labor versus antepartum fetal testing. Am J Obstet Gynecol (1987) 1.56
Chemoprophylaxis of malaria for travelers. Ann Intern Med (1974) 1.55
The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation (1985) 1.52
Pregnancy and lactation as determinants of bone mineral density in postmenopausal women. Am J Epidemiol (1992) 1.52
Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab (2000) 1.51
Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med (2001) 1.51
Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med (2013) 1.51
A prospective study of bone loss in menopausal Australian-born women. Osteoporos Int (1998) 1.50
Long-term postmenopausal hormone use, obesity, and fat distribution in older women. JAMA (1996) 1.48
The sex differential in mortality from all causes and ischemic heart disease. Am J Epidemiol (1983) 1.46
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int (2011) 1.45
Alcohol consumption and blood pressure. The lipid research clinics prevalence study. Hypertension (1982) 1.44
Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician (2000) 1.43
The association between blood pressure, age, and dietary sodium and potassium: a population study. Circulation (1988) 1.43
Coronal positioning of existing gingiva: short term results in the treatment of shallow marginal tissue recession. J Periodontol (1989) 1.42
25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology (2009) 1.40
Tolerability of risedronate in postmenopausal women intolerant of alendronate. Aging (Milano) (2001) 1.40
Current indications for hormone replacement therapy. Natl Med J India (1999) 1.39
Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med (1990) 1.39
"Evidence-based" or "logic-based" medicine? Osteoporos Int (2010) 1.38
Fasting plasma glucose, uric acid, and triglycerides as predictors of the ratio of total cholesterol to HDL-C. Am J Clin Pathol (1984) 1.37